ВЛИЯНИЕ НЕБИЛЕТА НА ДИСФУНКЦИЮ ЭНДОТЕЛИЯ И КИСЛОРОДТРАНСПОРТНУЮ ФУНКЦИЮ КРОВИ ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ
Аннотация
При дисфункции эндотелия у больных артериальной гипертензией наблюдаются существенные нарушения кислородтранспортной функции крови. Небилет улучшает функцию эндотелия, стимулирует продукцию NО, корригирует показатели кислородтранспортной функции крови, что повышает эффективность лечения и может оказать дополнительный протективный эффект в развитии сосудистых осложнений АГ.Литература
Манухина Е.Б., Лямина Н.П., Долотовская П.В. Роль оксида азота и кислородных свободных радикалов в патогенезе артериальной гипертензии // Кардиология. – 2002. - № 11. – С. 73-84.
Пронько Т.П. Эндотелийзависимая и эндотелийнезависимая вазодилатация у больных артериальной гипертензией в условиях патогенетической терапии // Медицинские новости. – 2003. – № 2. – C. 69-71.
Пронько Т.П., Лис М.А. Влияние b-селективного адреноблокатора небилета на функциональное состояние эндотелия у больных артериальной гипертензией // Здравоохранение. – 2003. – № 12. – С. 9-11.
Angelo M., Singel D.J., Stamler J.S. An S-nitrosothiol (SNO) synthase function of hemoglobin that utilizes nitrite as a substrate // PNAS. – 2006. – Vol. 103, № 22. - P. 8366-8371.
Arosio E., De Marchi S., Prior M., et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress // J. Hyperten. – 2002. – Vol. 9. – P. 1793-1797.
Cannon R.O. Role of nitric oxide in cardiovascular disease: focus on endothelium // Clin. Chem. – 1998. – Vol. 44. – P. 1809-1819.
Cardillo C., Kilcoyne C.M., Quyyumi A.A. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. // Circulation. – 1998.– Vol. 97, № 9 .– P. 851-856.
Cockroft J.R., Chowienczyk P.J., Brett S.E. Nebivolol vasodilates human foream vasculature: evidence for an L -arginine/No-dependent mechanism. // Amer. Soc. Pharmacol. Exp. Ther. – 1995. – Vol. 274, № 3. – P. 1067-1071.
Dawes M., Brett S., Chowiencyzk P. The vasodilatator action of nebivolol in forearm vasculature of subjects with essential hypertension – Br. J. Clin. Pharmacol. - 1999. - Vol. 48. – P. 460-463.
Gladwine M.T., Lancaster J.R., Freeman B.A., Schechter A.N. Nitric oxides reactions with hemoglobin: a view through The SNO-storm // Nat Med. – 2003. – V. 9. – P. 496-500.
Gladwin M.T., Crawford J.H., Patel R.P. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation // Free Radic. Biol. Med. – 2004. - Vol. 36, № 6. – P. 707-717.
Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide // Cardiovasc. Ther. – 2008. – V. 26(3). – P. 189-202.
Hatta T., Nakata T., Harada S. Lowering of blood pressure improves endothelial dysfunction by increase of nitric oxide production in hypertensive rats. // Hypertens. Res. – 2002. – Vol. 25, № 3. – P. 455-460.
Hermann M., Flammer A., Lьscher T. Nitric Oxide in Hypertension // J Clin Hypertens. – 2006. – V. 8, suppl 4. – P. 17–29.
Higashi Y., Sasaki S., Nakagawa K.A. comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicentre study. // J Am Coll Cardiol. – 2000. – Vol. 35. – P. 284-291.
Ignarro L.J., Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis // Curr. Diab. Rep. – 2005. – Vol. 5. – P. 17-23.
Kapila V., Sellke F.W., Suuronen E.J., Mesana T.G., Ruel M. Nitric oxide and the angiogenic response: can we improve the results of therapeutic angiogenesis? // Expert. Opin. Investig. Drugs. – 2005. – Vol. 14, № 1. – P. 37-44.
Landmesser U., Drexler H. The clinical significance of endothelial dysfunction // Curr. Opin. Cardiol. – 2005. – Vol. 20, № 6. – P. 547-551.
Landmesser U. Drexler H. Endothelial function and hypertension // Curr. Opin. Cardio. – 2007. – Vol. 22, № 4. – P. 316-320.
Lewington S., Clarke R., Qizilbash N., et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // Lancet. – 2002. – Vol. 360. – P. 1903–1913.
Naseem K.M. The role of nitric oxide in cardiovascular diseases // Molecular aspects of medicine. – 2005. – Vol. 26. – P. 33-65.
Panza J.A., Quyyumi A.A., Brush J.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. // N. Engl. J. Med. – 1990. – Vol. 323. – P. 22-27.
Paranti A., Filippi S., Amerini S. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivololl // The Journal of pharmacology and experimental therapeutics. – 2000. – Vol. 292. – P. 698-703.
Pasini A.F., Garbin U., Stranieri C., et al Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients // Am J Hypertens. – 2008. – Vol. 21, № 11. – P. 1251-1257.
Perticone F., Ceravolo R., Pujia A. Prognostic significance of endothelial dysfunction in hypertensive patients. // Circulation. – 2001. – Vol. 104, № 2. – P. 191-196.
Pronko T.P., Zinchuk V.V. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension // Clin Physiol Funct Imaging. – 2009. – Vol. 29. – P. 170-176.
Radaelli A., Mircoli L., Mori I. Nitric-oxide dependent vasodilatation in young spontaneously hypertensive rats // Hypertension. – 1998. – Vol. 32. – P. 735-739.
Semyonkin A., Zhivilova L., Novikov A. et al. Prognostic significance of endothelial dysfunction in essential hypertension // J. Hypertens. – 2008. – Vol. 26, № 1. – P. 290.
Spieker L.E., Flammer A.J., Luscher T.F. The vascular endothelium in hypertension // Handb Exp Pharmacol. – 2006. - Vol. 176, № 2. - P. 249-83.
Taddei S., Salvetti A. Endothelial dysfunction in essential hypertension : clinical implications // J Hypertension. – 2002. – V. 20. – P. 1-10.
Tzemos N., Lim P.O., MacDonald T.M. Nebivolol reverses endothelial dusfunction in essential hypertension: a randomized, double-blind, crossover study // Circulation. – 2001. – Vol. 104, № 5. – P. 511-514.
Ugrekhelidze J., Simonia G., Andronikashvili I., Kutateladze M. Influence of nebivolol on endothelial dysfunction in salt-sensitive hypertension // Georgian Med News. – 2006. - Vol. 133. – P. 56-58.
Vanhoutte P.M. Endothelial dysfunction // Circ J. – 2009. – Vol. 73, № 4. – P. 595-601.
Wojciechowski D., Papademetriou V. Beta-blockers in the management of hypertension: focus on nebivolol // Expert Rev Cardiovasc Ther. – 2008. – Vol. 6, № 4. – P. 471-479.
Zinchuk V.V., Dorochina L.V., Blood oxygen transport in rats under hypothermia combined with modification of the L-arginine-NO-pathway // Nitric Oxide. – 2002. Vol. 6, № 1. – P. 29-34.
Zinchuk V.V., Pronko T.P., Lis M.A. Blood oxygen transport and endothelial dysfunction in patients with arterial hypertension // Clin. Physiol. Funct. Imaging. – 2004. – Vol. 24, № 4. – P. 205-211.
Zinchuk V.V., Zinchuk N.V. Effect of nebivolol on the blood oxygen transport // Eksp Klin Farmakol. – 2007. – Vol. 70, № 1. - P. 44-47.
